Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

AC Immune Ltd

ACIU
Current price
3.87 USD +0.19 USD (+5.16%)
Last closed 3.54 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 365 925 920 USD
Yield for 12 month +82.55 %
1Y
3Y
5Y
10Y
15Y
ACIU
21.11.2021 - 28.11.2021

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. It is developing Crenezumab, a humanized, conformation-specific monoclonal antibody used to slow Alzheimer's disease (AD) progression; and Semorinemab, an investigational monoclonal anti-Tau antibody that targets the N-terminal portion of the Tau protein and is designed to bind to Tau and slow its spread between neurons for the treatment of AD. The company is also developing ACI-24.060 for the treatment of down syndrome-related AD; ACI-7104.056, to treat Parkinson's disease; and ACI-35.030, designs to stimulate a patient's immune system to produce antibodies against pathological phosphorylated Tau. In addition, it is developing diagnostic programs, consisting of PI-2620, a Tau diagnostic for AD, as well as non-AD Tauopathies; and ACI-12589, a-sync PET tracer that supports the differential diagnosis of multiple system atrophy from other neurodegenerative disease. Further, the company is researching and developing Morphomer Tau aggregation inhibitors to evaluate candidates in AD and NeuroOrphan Tauopathies. Additionally, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. The company has license agreements and collaborations with Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; and Eli Lilly and Company. AC Immune SA was incorporated in 2003 and is headquartered in Lausanne, Switzerland. Address: Building B, Lausanne, Switzerland, 1015

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

11.01 USD

P/E ratio

Dividend Yield

Current Year

+16 264 925 USD

Last Year

+4 324 200 USD

Current Quarter

Last Quarter

+16 264 925 USD

Current Year

-43 741 999 USD

Last Year

-61 979 461 USD

Current Quarter

Last Quarter

+172 528 USD

Key Figures ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -51 952 000 USD
Operating Margin TTM -23.92 %
PE Ratio
Return On Assets TTM -18.18 %
PEG Ratio
Return On Equity TTM -32.9 %
Wall Street Target Price 11.01 USD
Revenue TTM 14 801 000 USD
Book Value 1.71 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 1480000 %
Dividend Yield
Gross Profit TTM -56 401 000 USD
Earnings per share -0.67 USD
Diluted Eps TTM -0.67 USD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics ACIU

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation ACIU

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 10.9837
Price Sales TTM 18.3084
Enterprise Value EBITDA -3.1365
Price Book MRQ 1.546

Financials ACIU

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators ACIU

For 52 weeks

1.9 USD 5.14 USD
50 Day MA 2.82 USD
Shares Short Prior Month 506 172
200 Day MA 3.21 USD
Short Ratio 2.25
Shares Short 1 614 007
Short Percent 0.96 %

Dynamics of changes in the value of assets

Stocks


MSFT

MSFT

430.32 USD Microsoft Corporation +0.69 (+0.16%)
Detailed analytics

ETF funds


S

SX7EEX

14.75 EUR iShares EURO STOXX Banks 30-15 UCITS ETF (DE) 0 (0%)
Detailed analytics

Metals


Gold

2357.98 USD Gold +6.23 (+0.27%)
Detailed analytics